quartr
COPN: Recurring revenue up 18% YoY, strong cash, and pipeline advances reaffirm full-year outlook
Double-digit recurring revenue growth in H1 2026 was driven by Winlevi®, Lialda®, and CDMO, with strong cash reserves and no debt. Regulatory progress in dermatology and GI pipelines, and expansion of the GI Genius™ platform, support reaffirmed full-year guidance.Original document: Cosmo Pharmaceut…